We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.26 | 0.17% | 149.53 | 845 | 11:19:30 |
From May 2021 to May 2024
By Maria Armental
U.S. health regulators approved a label update for long-acting HIV treatment Cabenuva, allowing patients to start the injectable treatment without an oral lead-in phase.
Clinical data demonstrated a similar safety and efficacy profile with and without the oral lead-in period, according to the Food and Drug Administration.
Cabenuva is approved in the U.S. as a once-monthly or every-two-month treatment for HIV-1 in virologically suppressed adults on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to cabotegravir or rilpivirine.
It was developed by Johnson & Johnson's Janssen and ViiV Healthcare, which is majority owned by GlaxoSmithKline PLC.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
March 24, 2022 15:39 ET (19:39 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
